Steve is a Managing Director in Novartis Venture Fund's Cambridge, MA office, where he focuses on both medical device and therapeutic investments for the fund. He brings significant operating and venture capital experience to Novartis' investing efforts, having joined the Fund in 2006 as a Managing Director. He currently sits on the boards of Advanced Animal Diagnostics, Autonomic Technologies, Innocrin, Intersection Medical, and Viamet.
Prior to Novartis, Steve spent five years at Prism Venture Partners, where he focused on medical devices and served on the boards of iScience Interventional, ROX Medical, and Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds.
Steve started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy, and then rebuilt the business over the next five years.
Education, Personal, and Fellowship
Steve has an MBA, with Distinction, from the University of Michigan Business School and a BS in mechanical engineering from Columbia University's School of Engineering and Applied Science.
Steve serves on the University of Michigan Wolverine Venture Fund Advisory Board and on the board of the Family to Family Project.
Steve completed his fellowship under mentor Tom Smith at Mid-Atlantic Venture Funds in Reston, VA as a member of Class 5.